Downregulation of ERp57 expression is associated with poor prognosis in early-stage cervical cancer

Chung, Hwa‐Jin; Cho, Hanbyoul; Perry, Candice; Song, Jae Chul; Ylaya, Kris; Lee, Hee-Jeong; Kim, Jae Hoon

doi:10.3109/1354750x.2013.827742

Cited by 28 publications

(29 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The role of PDIA3 in the development and progression of human cancer has been suggested previously. Downregulation of the expression of PDIA3 is associated with a poor prognosis in early-stage cervical cancer (21). In addition, PDIA3 was found to contribute to epidermal growth factor receptor signaling and internalization in breast cancer cells (22).…”

Section: Discussionmentioning

confidence: 99%

MicroRNA-148a inhibits the proliferation and promotes the paclitaxel-induced apoptosis of ovarian cancer cells by targeting PDIA3

Zhao

Wen

Liu

et al. 2015

Molecular Medicine Reports

View full text Add to dashboard Cite

MicroRNAs (miRs) are a class of non-coding RNAs that function as key regulators of gene expression at the post-transcriptional level. miR-148a has been suggested to be associated with human ovarian cancer, however, the detailed functions of miR‑148a in ovarian cancer remain to be fully elucidated. The present study aimed to investigate the regulatory mechanism of miR-148a in ovarian cancer cells. Reverse transcription‑quantitative polymerase chain reaction and western blot analysis were conducted to examine the RNA and protein levels, respectively. The luciferase reporter assay was used to determine the target relationship. Cell proliferation and apoptosis assays were additionally conducted. The present study demonstrated that miR‑148a inhibited cell proliferation and promoted the paclitaxel‑induced apoptosis of ovarian cancer cells. Furthermore, protein disulfide isomerase family A, member 3 (PDIA3) was identified as a target gene of miR‑148a. A fluorescent reporter assay was performed to confirm that miR‑148a was able to directly bind to the 3'‑untranslated region of PDIA3 mRNA. In addition, miR‑148a was frequently downregulated in ovarian cancer tissue, whereas the expression levels of PDIA3 were increased. Knockdown of PDIA3 significantly inhibited the proliferation and promoted the paclitaxel‑induced apoptosis of the ovarian cancer cells, whereas overexpression of PDIA3 had the opposite effects. Therefore, the results of the present study suggested that miR‑148a inhibited the proliferation and promoted the paclitaxel‑induced apoptosis of ovarian cancer cells, and this may be partly attributed to direct targeting of PDIA3.

show abstract

Section: Discussionmentioning

confidence: 99%

MicroRNA-148a inhibits the proliferation and promotes the paclitaxel-induced apoptosis of ovarian cancer cells by targeting PDIA3

Zhao

Wen

Liu

et al. 2015

Molecular Medicine Reports

View full text Add to dashboard Cite

show abstract

“…Increased PDIA3 expression was associated with a poor prognosis in adenocarcinoma of the uterine cervix (23). However, its downregulation was associated with poor outcomes in squamous cell carcinoma of the uterine cervix (24), and loss of expression of PDIA3 is correlated with more aggressive forms of gastric cancer (25). Therefore, although PDIA3 is expressed in various types of cancer, the pathogenetic role of PDIA3 may vary among various types of human cancer, depending on the primary organs affected and the histology of the cancer.…”

Section: Discussionmentioning

confidence: 99%

Increased expression of PDIA3 and its association with cancer cell proliferation and poor prognosis in hepatocellular carcinoma

et al. 2016

View full text Add to dashboard Cite

The prognosis of hepatocellular carcinoma (HCC) is unfavorable following complete tumor resection. The aim of the present study was to identify a molecule able to predict HCC prognosis through comprehensive protein profiling and to elucidate its clinicopathological significance. Comprehensive protein profiling of HCC was performed by liquid chromatography-tandem mass spectrometry. Through the bioinformatic analysis of proteins expressed differentially in HCC and non-HCC tissues, protein disulfide-isomerase A3 (PDIA3) was identified as a candidate for the prediction of prognosis. PDIA3 expression was subsequently examined in 86 cases of HCC by immunostaining and associations between PDIA3 expression levels and clinicopathological characteristics were evaluated. The Ki-67 index and apoptotic cell death of carcinoma cells were examined by immunostaining and terminal deoxynucleotidyl transferase dUTP nick-end labeling assay in 24 cases. The results demonstrated that PDIA3 was expressed in all 86 HCC cases; 56 HCC cases (65%) exhibited high expression of PDIA3 and 30 (35%) exhibited low expression. The disease-free and overall survival times of HCC patients with high PDIA3 expression were significantly shorter than in HCC patients with low expression. Furthermore, increased expression of PDIA3 was associated with an elevated Ki-67 index, indicating increased cancer cell proliferation and a reduction in apoptotic cell death. Taken together, these results suggest that PDIA3 expression is associated with tumor proliferation and decreased apoptosis in HCC, and that increased expression of PDIA3 predicts poor prognosis. PDIA3 may therefore be a key molecule in the development of novel targeting therapies for patients with HCC.

show abstract

“…Interestingly, like CRT, the additional cellular role of CNX in ER stress has been implicated in cancer, with an increase in CNX expression linked with poor prognosis in colorectal cancer, and shown to be a diagnostic marker in lung cancer . The reduced expression of the thiol oxidoreductase, ERp57, that aids the formation of disulphide bonds to form the PLC, was shown to be an independent predictor of overall survival in cervical carcinoma and both the reduction and loss of ERp57 are correlated with progression of gastric cancer …”

Section: Mhc Class I Antigen Processing and Presentation In Tumour Immentioning

confidence: 99%

Antigen processing and immune regulation in the response to tumours

2016

View full text Add to dashboard Cite

SummaryThe MHC class I and II antigen processing and presentation pathways display peptides to circulating CD8 + cytotoxic and CD4 + helper T cells respectively to enable pathogens and transformed cells to be identified. Once detected, T cells become activated and either directly kill the infected / transformed cells (CD8 + cytotoxic T lymphocytes) or orchestrate the activation of the adaptive immune response (CD4 + T cells). The immune surveillance of transformed/tumour cells drives alteration of the antigen processing and presentation pathways to evade detection and hence the immune response. Evasion of the immune response is a significant event tumour development and considered one of the hallmarks of cancer. To avoid immune recognition, tumours employ a multitude of strategies with most resulting in a down-regulation of the MHC class I expression at the cell surface, significantly impairing the ability of CD8 + cytotoxic T lymphocytes to recognize the tumour. Alteration of the expression of key players in antigen processing not only affects MHC class I expression but also significantly alters the repertoire of peptides being presented. These modified peptide repertoires may serve to further reduce the presentation of tumour-specific/associated antigenic epitopes to aid immune evasion and tumour progression. Here we review the modifications to the antigen processing and presentation pathway in tumours and how it affects the anti-tumour immune response, considering the role of tumour-infiltrating cell populations and highlighting possible future therapeutic targets.

show abstract

Downregulation of ERp57 expression is associated with poor prognosis in early-stage cervical cancer

Abstract: Low ERp57 expression independently predicts a poor outcome for patients with cervical cancer, supporting the notion that ERp57 may be a promising novel cancer target.

Cited by 28 publications

References 16 publications

MicroRNA-148a inhibits the proliferation and promotes the paclitaxel-induced apoptosis of ovarian cancer cells by targeting PDIA3

MicroRNA-148a inhibits the proliferation and promotes the paclitaxel-induced apoptosis of ovarian cancer cells by targeting PDIA3

Increased expression of PDIA3 and its association with cancer cell proliferation and poor prognosis in hepatocellular carcinoma

Antigen processing and immune regulation in the response to tumours

Contact Info

Product

Resources

About